IntraBio https://validator.w3.org/feed/docs/rss2.html Home Cass Fields Results from the Global Phase 3 Trial (IB1001-303) Evaluating Levacetylleucine in Children and Adults with Ataxia-Telangiectasia Long-Term 30-Month Findings of N-acetyl-L-leucine for Niemann-Pick Disease Type C Virtual Patent Marking Our Team Results from the Global Phase 3 Clinical Trial (IB1001-303) Evaluating Levacetylleucine in Ataxia-Telangiectasia Measuring Functional Abilities and Assistance Level in Niemann-Pick disease type C, GM2 gangliosidoses, and Ataxia State Compliance N-acetyl-l-leucine lowers pS129-synuclein and improves synaptic function in models of Parkinson’s disease Taylor Fields IntraBio Announces Positive Pivotal Trial Results of Levacetylleucine for the Treatment of Ataxia-Telangiectasia IntraBio Receives European Commission Approval of AQNEURSA® for the Treatment of Niemann-Pick Type C Disease Expanded Access Program of Levacetylleucine in Ataxia-Telangiectasia Expanded Access Policy Long-Term Findings of N-Acetyl-L-Leucine for Niemann-Pick Disease Type C Subdomain Analysis of the 5-Domain Niemann-Pick Disease Type C Clinical Severity Scale Evaluating the Long-Term Effects of N-Acetyl-L-Leucine in Niemann-Pick Disease Type C SARA Subgroup Analysis Based on Disease Duration in a Phase 2 Trial Evaluating N-Acetyl-L-Leucine in GM2 Gangliosidoses Subgroup Evaluation of Adults and Children with Niemann-Pick Disease Type C in the Phase 3 (IB1001-301) Extension Phase Assessing N-Acetyl-L-Leucine The Functional Independence Measure for Children (WeeFIM®) in Niemann-Pick Disease Type C Receiving Levacetylleucine Long-term (30 Months) Outcomes of N-acetyl-L-leucine in Adults and Children with Niemann-Pick Disease Type C Privacy Policy Pipeline Cookies Policy Our Products N-Acetyl-L-Leucine for Ataxia-Telangiectasia: A Multinational, Double-Blind, Randomized, Placebo-Controlled, Crossover Study Subgroup Analysis by Phenotype in a Phase III, Randomized, Placebo-Controlled Crossover Trial with Levacetylleucine (IB1001) for Niemann-Pick Disease Type C Subgroup Analysis of Pediatric Patients in a Phase III, Randomized, Placebo-Controlled Crossover Trial with Levacetylleucine (IB1001) for Niemann-Pick Disease Type C Long-Term 24-Month Findings of N-acetyl-L-leucine for Niemann-Pick Disease Type C Long-Term 52-Week Findings on N-Acetyl-L-Leucine for GM2 Gangliosidoses SCAFI Subtest and SARA Eight-Item Subgroup Analysis of N-Acetyl-L-Leucine in Phase II, Randomized, Rater-Blinded Crossover Trial for GM2 Gangliosidoses Long-Term 52-Week Findings on N-Acetyl-L-Leucine for GM2 Gangliosidoses (Tay-Sachs and Sandhoff Disease) Long-Term 24-Month Findings of N-acetyl-L-leucine for Niemann-Pick Disease Type C SARA Eight-Item Subgroup Analysis of N-Acetyl-L-Leucine for Niemann-Pick Disease Type C Subgroup and Subdomain Analysis of Patients in a Phase III, Randomized, Placebo-Controlled Crossover Trial with Levacetylleucine (IB1001) for Niemann-Pick Disease Type C With Long Term Follow-Up Acetyl-Leucine Improves Cerebellar Dysarthria in MSA-C Lead Program Therapeutic potential of acetyl-DL-leucine and its L-enantiomer in posterior fossa syndrome: Mechanistic insights Stereospecific rapid activation of Transcription Factor EB (TFEB) by Levacetylleucine (NALL) N-Acetyl-l-Leucine (NALL) rescues inter-organelle communication in Niemann-Pick disease type-C patient cells Disease-Modifying, Neuroprotective Effect of N-Acetyl-l-Leucine in Adult and Pediatric Patients With Niemann-Pick Disease Type C Tourette syndrome: effects of acetyl-leucine in two individuals Prof. Mallory Factor KCN Stephen Hahn Prof. Michael Strupp MD FRCP FANA FEAN Mark Lubkeman Scientific Presentations Trends in Pharmacological Sciences Drug of the Month: Levacetylleucine (N-acetyl-L-leucine) for Niemann-Pick disease type C Contact “How to save a marriage”: treatment of REM sleep behavior disorder (RBD) with acetyl-leucine in a patient with Parkinson’s disease